Skip to content
Toggle Navigation
Platform
Pipeline
Our Team
Our Story
Partnerships
News
Careers
Contact
Back to News
Categories:
News
|
Published On:
June 12
,
2024
|
Written by
webadmin@biolojic.com
|
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Back to News
More News
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.
Read More
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
Read More
BUSINESS AND MEDIA INQUIRIES
Micah Pearlman
micah@biolojic.com
Page load link
Go to Top